Oppenheimer analyst Leland Gershell downgraded Rhythm Pharmaceuticals (NASDAQ: RYTM) from Outperform to Perform.The analyst comments: "RYTM has admirably outperformed YTD ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE